Amgen has reached a deal with the Federal Trade Commission that will enable the pharmaceutical company to complete its $28 billion acquisition of Horizon, according to statements from both parties.
The agreement follows a lawsuit from the FTC, filed in May, alleging that the merger would reduce competition for therapies intended to treat gout and thyroid eye disease.
Under the new settlement, Amgen will be prohibited from bundling any of its products with teprotumumab-trbw (Tepezza) and pegloticase (Kyrtexxa), Horizon’s therapies that treat thyroid eye disease and gout, respectively. In